Page 309 - Read Online

Page 14 of 18 Qureshy et al. J Cancer Metastasis Treat 2020;6:27 I http://dx.doi.org/10.20517/2394-4722.2020.58

49. Pan YM, Wang CG, Zhu M, Xing R, Cui JT, et al. STAT3 signaling drives EZH2 transcriptional activation and mediates poor prognosis
in gastric cancer. Mol Cancer 2016;15:79.
50. Shien K, Papadimitrakopoulou VA, Ruder D, Behrens C, Shen L, et al. JAK1/STAT3 activation through a proinflammatory cytokine
pathway leads to resistance to molecularly targeted therapy in non-small cell lung cancer. Mol Cancer Ther 2017;16:2234-45.
51. He W, Wu J, Shi J, Huo YM, Dai W, et al. IL22RA1/STAT3 signaling promotes stemness and tumorigenicity in pancreatic cancer. Cancer
Res 2018;78:3293-305.
52. Lu C, Talukder A, Savage NM, Singh N, Liu K. JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to
decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer. Oncoimmunology 2017;6:e1291106.
53. Lin XM, Chen H, Zhan XL. MIR-203 regulates JAK-STAT pathway in affecting pancreatic cancer cells proliferation and apoptosis by
targeting SOCS3. Eur Rev Med Pharmacol Sci 2019;23:6906-13.
54. Peyser ND, Freilino M, Wang L, Zeng Y, Li H, et al. Frequent promoter hypermethylation of PTPRT increases STAT3 activation and
sensitivity to STAT3 inhibition in head and neck cancer. Oncogene 2016;35:1163-9.
55. Peyser ND, Du Y, Li H, Lui V, Xiao X, et al. Loss-of-function PTPRD mutations lead to increased STAT3 activation and sensitivity to
STAT3 inhibition in head and neck cancer. PLoS One 2015;10:e0135750.
56. Gyamfi J, Lee YH, Eom M, Choi J. Interleukin-6/STAT3 signalling regulates adipocyte induced epithelial-mesenchymal transition in
breast cancer cells. Sci Rep 2018;8:8859.
57. Jiang C, Long J, Liu B, Xu M, Wang W, et al. miR-500a-3p promotes cancer stem cells properties via STAT3 pathway in human
hepatocellular carcinoma. J Exp Clin Cancer Res 2017;36:99.
58. Saini U, Naidu S, Elnaggar AC, Bid HK, Wallbillich JJ, et al. Elevated STAT3 expression in ovarian cancer ascites promotes invasion and
metastasis: a potential therapeutic target. Oncogene 2017;36:168-81.
59. Escher TE, Lui AJ, Geanes ES, Walter KR, Tawfik O, et al. Interaction between MUC1 and STAT1 drives IFITM1 overexpression in
aromatase inhibitor-resistant breast cancer cells and mediates estrogen-induced apoptosis. Mol Cancer Res 2019;17:1180-94.
60. Chen X, Huang J, Yuchun L. High expression of STAT2 in ovarian cancer and its effect on metastasis of ovarian cancer cells. Nan Fang
Yi Ke Da Xue Xue Bao 2020;40:34-41. (in Chinese)
61. Yang M, Chen H, Zhou L, Chen K, Su F. Expression profile and prognostic values of STAT family members in non-small cell lung
cancer. Am J Transl Res 2019;11: 4866-80.
62. Haddad BR, Erickson A, Udhane V, LaViolette PS, Rone JD, et al. Positive STAT5 protein and locus amplification status predicts
recurrence after radical prostatectomy to assist clinical precision management of prostate cancer. Cancer Epidemiol Biomarkers Prev
2019;28:1642-51.
63. Liao Z, Lutz J, Nevalainen MT. Transcription factor Stat5a/b as a therapeutic target protein for prostate cancer. Int J Biochem Cell Biol
2010;42:186-92.
64. Li BH, Yang XZ, Li PD, Yuan Q, Liu XH, et al. IL-4/Stat6 activities correlate with apoptosis and metastasis in colon cancer cells.
Biochem Biophys Res Commun 2008;369:554-60.
65. von Bubnoff N, Ihorst G, Grishina O, Röthling N, Bertz H, et al. Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase
2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-
versushost disease (aGvHD) (NCT02396628). BMC Cancer 2018;18:1132.
66. Lim ST, Jeon YW, Gwak H, Kim SY, Suh YJ. Synergistic anticancer effects of ruxolitinib and calcitriol in estrogen receptor-positive,
human epidermal growth factor receptor 2-positive breast cancer cells. Mol Med Rep 2018;17:5581-8.
67. Kim JW, Gautam J, Kim JE, Kim JA, Kang KW. Inhibition of tumor growth and angiogenesis of tamoxifen-resistant breast cancer cells
by ruxolitinib, a selective JAK2 inhibitor. Oncol Lett 2019;17:3981-9.
68. Taverna JA, Hung CN, DeArmond DT, Chen M, Lin CL, et al. Single-cell proteomic profiling identifies combined AXL and JAK1
inhibition as a novel therapeutic strategy for lung cancer. Cancer Res 2020;80:1551-63.
69. Vallath S, Sage EK, Kolluri KK, Lourenco SN, Teixeira VS, et al. CADM1 inhibits squamous cell carcinoma progression by reducing
STAT3 activity. Sci Rep 2016;6:24006.
70. Yang PW, Huang PM, Yong LS, Chang YH, Wu CW, et al. Circulating interleukin-6 is associated with prognosis and genetic
polymorphisms of MIR608 in patients with esophageal squamous cell carcinoma. Ann Surg Oncol 2018;25:2449-56.
71. Ojha R, Singh SK, Bhattacharyya S. JAK-mediated autophagy regulates stemness and cell survival in cisplatin resistant bladder cancer
cells. Biochim Biophys Acta - Gen Subj 2016;1860:2484-97.
72. Wilson GS, Tian A, Hebbard L, Duan W, George J, et al. Tumoricidal effects of the JAK inhibitor Ruxolitinib (INC424) on hepatocellular
carcinoma in vitro. Cancer Lett 2013;341:224-30.
73. Morgan EL, Macdonald A. JAK2 inhibition impairs proliferation and sensitises cervical cancer cells to cisplatin-induced cell death.
Cancers (Basel) 2019;11:1934.
74. An HJ, Choi EK, Kim JS, Hong SW, Moon JH, et al. INCB018424 induces apoptotic cell death through the suppression of pJAK1 in
human colon cancer cells. Neoplasma 2014;61:56-62.
75. Radhakrishnan H, Ilm K, Walther W, Shirasawa S, Sasazuki T, et al. MACC1 regulates Fas mediated apoptosis through STAT1/3 - Mcl-1
signaling in solid cancers. Cancer Lett 2017;403:231-45.
76. Gore J, Craven KE, Wilson JL, Cote GA, Cheng M, et al. TCGA data and patient-derived orthotopic xenografts highlight pancreatic
cancer-associated angiogenesis. Oncotarget 2015;6:7504-21.
77. Perusina Lanfranca M, Zhang Y, Girgis A, Kasselman S, Lazarus J, et al. Interleukin 22 signaling regulates acinar cell plasticity to
promote pancreatic tumor development in mice. Gastroenterology 2020;158:1417-32.e11.